South Korea’s Onconic Soars 30% as FDA Backs Nesuparib for Small Cell Lung Cancer

Onconic Therapeutics Inc. (476060:KQ) shares reached the daily price limit on Tuesday after the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to its lead oncology candidate, Nesuparib, for the treatment of small cell lung cancer (SCLC).

The clinical milestone impacts a critical segment of the oncology market, as SCLC accounts for approximately 15% of all lung cancer diagnoses annually. On February 24, the company’s stock climbed 29.98% to 25,450 won (approximately $19 USD) on the KOSDAQ market, reflecting investor confidence in a drug that now holds three separate FDA orphan status distinctions.

Expanding the “Pan-Tumor” Pipeline

This latest regulatory win marks the third ODD for Nesuparib, following similar designations for pancreatic cancer in 2021 and gastric cancer in 2025. Onconic Therapeutics currently positions the drug as a “pan-tumor” therapeutic, designed to address various high-need malignancies through a unique dual-inhibition mechanism.

Small cell lung cancer remains a notoriously difficult-to-treat disease. While patients typically respond well to initial chemotherapy, the majority face rapid relapse with few effective second-line options. The FDA’s designation validates the biological rationale for Nesuparib in this space, particularly for patients with genomic instability caused by the loss of TP53 and RB1 genes.

Dual-Action Mechanism: PARP and Tankyrase

Unlike first-generation treatments that target only a single survival pathway, Nesuparib inhibits both poly(ADP-ribose) polymerase (PARP) and tankyrase (TNKS).

• PARP Inhibition: Prevents cancer cells from repairing single-strand DNA breaks.
• TNKS Inhibition: Regulates the Wnt and Hippo signaling pathways, which often drive tumor growth and drug resistance.

By attacking these two axes simultaneously, Nesuparib seeks to induce selective cell death in tumors that have developed resistance to standard PARP inhibitors.

From Seoul-Based R&D to Global Contender

The recent FDA designation marks a high-water mark for Onconic Therapeutics Inc., a South Korean biotech firm founded in May 2020. Operating as a specialized subsidiary of Jeil Pharmaceutical Co., Ltd., Onconic focuses on high-growth areas of oncology and acid-related diseases. The company successfully completed a KRW 27.5 billion (approximately $20.5 million USD) Series A round in 2021, fueling the aggressive development of its synthetic lethality pipeline. By leveraging the manufacturing and commercial infrastructure of its parent company, Jeil, Onconic is positioning itself to pivot from a regional R&D lab to a significant player in the global oncology market.

Strategic Advantages of Orphan Drug Status

The Orphan Drug Act provides significant commercial and regulatory tailwinds for biotech firms. Upon final approval, Nesuparib will receive seven years of market exclusivity in the U.S. for the SCLC indication. This protection prevents competitors from launching “same-drug” versions for the same use, a policy recently clarified by the Consolidated Appropriations Act of 2026.

Furthermore, ODD status allows for:

• Tax credits for qualified clinical testing expenses.
• Waivers of the multi-million dollar Prescription Drug User Fee.
• Potential for conditional approval based on Phase 2 clinical trial results, significantly shortening the timeline to market.

The Landscape of Next-Generation PARP Inhibitors

As first-generation PARP inhibitors like AstraZeneca’s Lynparza and GSK’s Zejula face challenges with drug resistance and hematological toxicity, the industry is shifting toward “selective” or “dual-target” agents. These next-generation drugs aim to improve the therapeutic window by sparing healthy cells while intensifying the attack on tumor DNA.

Competitive Comparison: PARP and Dual-Targeting Pipelines

While AstraZeneca and Pfizer focus on making PARP inhibitors more “selective” to reduce side effects, Onconic’s strategy is additive. By inhibiting Tankyrase alongside PARP, Nesuparib addresses the “plasticity” of cancer cells—their ability to change and survive even when one DNA repair pathway is blocked.

Market Outlook and Future Catalysts

The global SCLC therapeutics market expects a surge in value, with projections rising from $8.14 billion in 2026 to approximately $22.86 billion by 2035. Investors view Onconic’s entry into this space as a high-stakes move that could redefine second-line treatment protocols.

The pharmaceutical industry now looks toward Onconic’s ongoing trials, notably the PENELOPE Phase 2 study (NCT06551142), which evaluates Nesuparib in combination with pembrolizumab for endometrial cancer.

1. Combination Studies: Onconic is evaluating Nesuparib in combination with Celltrion’s Vegzelma and MSD’s Keytruda. Success here would prove the drug’s versatility as a backbone for multi-drug regimens.
2. SCLC Clinical Entry: Following the ODD, the company plans to accelerate clinical protocols specifically for recurrent SCLC patients who currently lack secondary treatment options.
3. Global Licensing: Given the high medical demand, analysts anticipate potential out-licensing deals with major global pharmaceutical players seeking to bolster their oncology portfolios.

“The FDA recognizes the potential of our dual-targeting mechanism to suppress the core survival axes of cancer cells,” stated an official from Onconic Therapeutics. The company intends to continue expanding its indications to cancers with high replication stress, aiming to bridge the gap in current treatment protocols.

Author

Bernice Lottering